Selected STA™/Mutector™ Publications

1. Herreros-Villanueva M, Chen CC, Yuan SS, Liu TC, Er TK. (2014). KRAS mutations: analytical considerations. Clin Chim Acta. 431:211

2. Jylling AMB, Rasmussen AA, Jakobsen EH, René dePont Christensen, Rd, and Flemming Brandt Sørensen FB. (2014). Are mutations in K-RAS, BRAF and PIK3CA genes critical for response to adjuvant trastuzumab treatment in patients with HER-2 positive breast cancer? JCTR 3

3. Raparia K, Villa C, Raj R, Cagle PT. (2014). Peripheral Lung Adenocarcinomas With KRAS Mutations Are More Likely to InvadeVisceral Pleura. Arch Pathol Lab Med. 2014 Apr 2. [Epub ahead of print]

4. Puri A, Saif MW. (2014). Pharmacogenomics update in pancreatic cancer. JOP. **15**:114

5. Tseng D, Kim J, Warrick A, Nelson D, Pukay M, Beadling C, Heinrich M, Selim MA, Corless CL, Nelson K. (2014). Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. J Am Acad Dermatol. 2014 May 17.[Epub ahead of print]

6. Bowles DW, Ma WW, Senzer N, Brahmer JR, Adjei AA, Davies M, Lazar AJ, Vo A, Peterson S, Walker L, Hausman D, Rudin CM, Jimeno A. (2013). A multicenter phase 1 study of PX-866 in combination with docetaxel inpatients with advanced solid tumours. Br J Cancer. **109**:1085

7. Huang T, Karsy M, Zhuge J, Zhong M, Liu D. (2013). B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. **6**:30

8. Kang SY, Ahn S, Lee SM, Jeong JY, Sung JY, Oh YL, Kim KM (2013). Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas. Diagn Pathol. **8**:121

9. Kim TE, Jung ES, Jung CK, Bae JS, Kim SN, Kim GS, Lee HN, Kang CS, Choi YJ. (2013). DHPLC is a highly sensitive and rapid screening method to detect BRAF(V600E) mutation in papillary thyroid carcinoma. Exp Mol Pathol. **94**:203

10. Wang J, Yang H, Shen Y, Wang S, Lin D, Ma L, Han X, Shi Y. (2013). Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. Cancer Biomark. **13**:89

11. Alexander RE, Lopez-Beltran A, Montironi R, MacLennan GT, Post KM, Bilbo SA, Jones TD, Huang W, Rao Q, Sen JD, Meehan K, Cornwell A, Miravalle L, Cheng L. (2012). KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. Histopathology. **61**:1036

12. Brait M, Loyo M, Rosenbaum E, Ostrow KL, Markova A, Papagerakis S, Zahurak M, Goodman SM, Zeiger M, Sidransky D, Umbricht CB, Hoque MO. (2012). Correlation

between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer. Epigenetics. **7**:710

13. Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D'Cruz A, Rajan MG. (2012). BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol. **23**:83

14. Davidson CJ, Zeringer E, Champion KJ, Gauthier MP, Wang F, Boonyaratanakornkit J, Jones JR, Schreiber E.(2012). Improving the limit of detection for Sanger sequencing: a comparison of methodologies for KRAS variant detection. Biotechniques. **53**:182

15. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. (2012). A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients withadvanced solid tumors. Clin Cancer Res. **15**:4173

16. Lee KC, Li C, Schneider EB, Wang Y, Somervell H, Krafft M, Umbricht CB, Zeiger MA. (2012).Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroidcancer? Surgery. **152**:977

17. Miravalle L, Lefferts JA, Al-Haddad M, Tsongalis GJ, Cheng L. (2012). KRAS testing in clinical laboratory: optimizing targeted therapy. Cancer Genomics Proteomics. **9**:337

18. Pang B, Ong CW, Chong ML, Muliana-Ismail T, Soong R, Salto-Tellez M. (2012). KRAS mutation analysis in a complex molecular diagnostic referralpractice: the need for test redundancy. Pathology. **44**:655

19. Shaukat A, Arain M, Anway R, Manaktala S, Pohlman L, Thyagarajan B. (2012). Is KRAS mutation associated with interval colorectal cancers? Dig Dis Sci. **57**:913

20. Goia-Ruşanu CD, Iancu IV, Botezatu A, Socolov D, Huică I, Pleşa A, Anton G. (2011). Mitochondrial DNA mutations in patients with HRHPV-related cervical lesions. Roum Arch Microbiol Immunol. **70**:5

21. Kulesza P, Ramchandran K, Patel JD. (2011). Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. Am J Clin Pathol. **136**:228

22. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, Saida T, Takata M. (2011). Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer. **104**:464

23. Schlosshauer PW, Deligdisch L, Penault-Llorca F, Fatemi D, Qiao R, Yao S, Pearl M, Yang Z, Sheng T, Dong J. (2011). Loss of p16INK4A expression in low-grade ovarian serous carcinomas. Int J Gynecol Pathol. **30**:22

24. Sobin C, Parisi N, Schaub T, Gutierrez M, Ortega AX. (2011). δ-Aminolevulinic acid dehydratase single nucleotide polymorphism 2 and peptide

transporter 2*2 haplotype may differentially mediate lead exposure in male children. Arch Environ Contam Toxicol. **61**:521

25. Vranic S, Gatalica Z, Wang ZY. (2011). Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. Oncol Lett. **2**:1131

26. Wiita AP, Schrijver I. (2011). Clinical application of high throughput molecular screening techniques forpharmacogenomics. Pharmgenomics Pers Med. **4**:109

27. Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK. (2010). Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer. **116**:5179

28. Gilfillan CP. (2010). Review of the genetics of thyroid tumours: diagnostic and prognostic implications. ANZ J Surg. **80**:33

29. Ollar RA, Cooperman AM, Wayne ME, Barrecchia JF, Sonpal N, Duddempudi S, Kasmin FE. (2010). A colorimetric method for detection of K-ras codon 12 point mutations in DNA extracted from tissue and peripheral blood in pancreatic disorders. Biochem Genet. **48**:577

30. Mekel M, Nucera C, Hodin RA, Parangi S. (2010). Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg. **200**:136

31. Shaukat A, Arain M, Thaygarajan B, Bond JH, Sawhney M. (2010). Is BRAF mutation associated with interval colorectal cancers? Dig Dis Sci. **55**:2352

32. Funami J, Hayashi T, Nomura H, Ding QF, Ishitsuka-Watanabe A, Matsui-Hirai H, Ina K, Zhang J, Yu ZY, Iguchi A. (2009). Clinical factors such as B-type natriuretic peptide link to factor VII, endothelial NO synthase and estrogen receptor alpha polymorphism in elderly women. Life Sci. **85**:316

33. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. (2009). Absence of the BRAF mutation in HBME1+ and CK19+ atypical cell clusters in Hashimoto thyroiditis: supportive evidence against preneoplastic change. Am J Clin Pathol. **132**:906

34. Sobin C, Gutierrez M, Alterio H. (2009). Polymorphisms of delta-aminolevulinic acid dehydratase (ALAD) and peptide transporter 2(PEPT2) genes in children with low-level lead exposure. Neurotoxicology. **30**:881

35. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R. (2009). BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens forpreoperative risk stratification in papillary thyroid cancer. J Clin Oncol. **27**:2977

36. Cohen Y, Merhavi-Shoham E, Avraham RB, Frenkel S, Pe'er J, Goldenberg-Cohen N. (2008). Hypermethylation of CpG island loci of multiple tumor suppressor genes in retinoblastoma. Exp Eye Res. **86**:201

37. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D. (2008). Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab. **19**:138

38. Krishnamurthy S. (2007). Applications of molecular techniques to fine-needle aspiration biopsy. Cancer. **111**:106

39. Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M, Bommarito A, Citarrella R, Lo Coco R, Cabibi D, Lo Coco A, Frasca F, Gulotta G, Latteri MA, Modica G, Galluzzo A, Giordano C. (2007). Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid. **17**:1109

40. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C. (2007). BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid factor 1alpha and their paired lymph node metastases. Cancer. 2007 **110**:1218

41. Wu J, Rosenbaum E, Begum S, Westra WH. (2007). Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi:implications for melanocytic tumorigenesis. Am J Dermatopathol. **29**:534

42. Yoshimoto T, Takahashi M, Nagayama S, Watanabe G, Shimada Y, Sakasi Y, Kubo H. (2007). RNA mutations of prox1 detected in human esophageal cancer cells by the shifted termination assay. Biochem Biophys Res Commun. **359**:258

43. Ichii-Nakato N, Takata M, Takayanagi S, Takashima S, Lin J, Murata H, Fujimoto A, Hatta N, Saida T. (2006). High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol. **126**:2111

44. Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, Johnson MR, Lloyd RV. (2006). BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol. **15**:136

45. Benoit NE, Goldenberg D, Deng SX, Rosenbaum E, Cohen Y, Califano JA, Shackelford WH, Wang XB, Sidransky D. (2005). Colorimetric approach to high-throughput mutation analysis. Biotechniques. **38**:635

46. Davison JM, Rosenbaum E, Barrett TL, Goldenberg D, Hoque MO, Sidransky D, Westra WH. (2005). Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer. **103**:788

47. Goldenberg-Cohen N, Cohen Y, Rosenbaum E, Herscovici Z, Chowers I, Weinberger D, Pe'er J, Sidransky D. (2005). T1799A BRAF mutations in conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci. **46**:3027

48. Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, Zeiger MA, Sidransky D, Umbricht CB. (2005). Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab. **90**:4011

49. Rosenbaum E, Hosler G, Zahurak M, Cohen Y, Sidransky D, Westra WH. (2005). Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol. **18**:898

50. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. (2005). BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. **90**:6373

51. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. (2004). BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol. **17**:1359

52. Cohen Y, Rosenbaum E, Begum S, Goldenberg D, Esche C, Lavie O, Sidransky D, Westra WH. (2004). Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res. **10**:3444

53. Goldenberg D, Rosenbaum E, Argani P, Wistuba II, Sidransky D, Thuluvath PJ, Hidalgo M, Califano J, Maitra A. (2004). The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol. **17**:1386

54. Shackelford W, Deng S, Murayama K, Wang J. (2004). A new technology for mutation detection. Ann N Y Acad Sci. **1022**:257

55. Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D, Ladenson PW. (2004). Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostictool for papillary thyroid cancer. J Clin Endocrinol Metab. **89**:2867